Europe set to approve a new mRNA vaccine for human use
In late February, the European Medicines Agency (EMA) recommended granting marketing authorisation for a vaccine marketed under the name mCombriax. This is an mRNA “vaccine” against COVID-19 and seasonal flu, developed by Moderna, intended for people aged 50 and over. This opinion will be forwarded to the European Commission, which could adopt the marketing authorisation decision. Given that mRNA technology is still in its infancy and has not yet really proven itself in the medical field, this favourable opinion is somewhat surprising.
